Showing 13,301 - 13,320 results of 21,342 for search '(( significantly ((we decrease) OR (a decrease)) ) OR ( significant decrease decrease ))', query time: 0.54s Refine Results
  1. 13301

    Table 1_The health burden of disease attributable to low calcium intake: a comprehensive analysis of trends and socioeconomic impacts from 1990 to 2021.docx by Yanping Wang (275956)

    Published 2025
    “…Prostate cancer and DLC showed a negative directional trend but lacked statistical significance. …”
  2. 13302

    Table 1_High-dose thiamine supplementation ameliorates obesity induced by a high-fat and high-fructose diet in mice by reshaping gut microbiota.xlsx by Yu Xia (8822)

    Published 2025
    “…Our previous study identified significantly lower levels of fecal thiamine in individuals with obesity; however, its potential and mechanisms for alleviating obesity induced by a high-fat and high-fructose diet (HFFD) remain unclear. …”
  3. 13303

    Image 1_High-dose thiamine supplementation ameliorates obesity induced by a high-fat and high-fructose diet in mice by reshaping gut microbiota.tif by Yu Xia (8822)

    Published 2025
    “…Our previous study identified significantly lower levels of fecal thiamine in individuals with obesity; however, its potential and mechanisms for alleviating obesity induced by a high-fat and high-fructose diet (HFFD) remain unclear. …”
  4. 13304

    Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex<sup>®</sup>) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”
  5. 13305

    Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex<sup>®</sup>) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”
  6. 13306

    Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex<sup>®</sup>) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”
  7. 13307

    Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx by Øystein Fluge (200378)

    Published 2025
    “…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex<sup>®</sup>) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”
  8. 13308

    Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex<sup>®</sup>) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”
  9. 13309
  10. 13310

    Table 1_Impact of dual residual risk of cholesterol and inflammation on adult male sex hormones: a cross-sectional study from NHANES.docx by Yang Zhou (65942)

    Published 2025
    “…In the presence of both risk factors (BR), TT decreased most significantly (β = -79.37, 95% CI [-112.74, -46.00], p < 0.0001), as did FT in the same subgroup (β = -1.00, 95% CI [-1.61, -0.40], p = 0.0012). …”
  11. 13311

    Supplementary file 1_Association of prenatal trajectories of depressive and anxiety symptoms with neurodevelopment of children aged 0-24 months: A prospective study.docx by Ruoqing Chen (9952075)

    Published 2025
    “…Background<p>Prenatal depression and anxiety can significantly impact a child’s neurodevelopment. However, the specific timing and patterns of these maternal psychological symptoms during pregnancy that influence the child’s neurodevelopment remain unclear. …”
  12. 13312

    Table 3_Effects of extracorporeal carbon dioxide removal in facilitating ultra-protective ventilation strategies for patients with acute respiratory distress syndrome: a systematic... by Weifeng Zhen (12969341)

    Published 2025
    “…Ultra-protective ventilation (≤4 mL/kg predicted body weight) has the potential to further decrease ventilator-induced lung injury but may result in severe hypercapnia. …”
  13. 13313

    Table 1_Effects of extracorporeal carbon dioxide removal in facilitating ultra-protective ventilation strategies for patients with acute respiratory distress syndrome: a systematic... by Weifeng Zhen (12969341)

    Published 2025
    “…Ultra-protective ventilation (≤4 mL/kg predicted body weight) has the potential to further decrease ventilator-induced lung injury but may result in severe hypercapnia. …”
  14. 13314

    Table 2_Effects of extracorporeal carbon dioxide removal in facilitating ultra-protective ventilation strategies for patients with acute respiratory distress syndrome: a systematic... by Weifeng Zhen (12969341)

    Published 2025
    “…Ultra-protective ventilation (≤4 mL/kg predicted body weight) has the potential to further decrease ventilator-induced lung injury but may result in severe hypercapnia. …”
  15. 13315

    Table 4_Effects of extracorporeal carbon dioxide removal in facilitating ultra-protective ventilation strategies for patients with acute respiratory distress syndrome: a systematic... by Weifeng Zhen (12969341)

    Published 2025
    “…Ultra-protective ventilation (≤4 mL/kg predicted body weight) has the potential to further decrease ventilator-induced lung injury but may result in severe hypercapnia. …”
  16. 13316

    Table 5_Effects of extracorporeal carbon dioxide removal in facilitating ultra-protective ventilation strategies for patients with acute respiratory distress syndrome: a systematic... by Weifeng Zhen (12969341)

    Published 2025
    “…Ultra-protective ventilation (≤4 mL/kg predicted body weight) has the potential to further decrease ventilator-induced lung injury but may result in severe hypercapnia. …”
  17. 13317

    Image 2_The clinical features and outcomes of diabetes patients infected with COVID-19: a systematic review and meta-analysis comprising 192,693 patients.tif by Kai Liu (159026)

    Published 2025
    “…Common comorbidities in the diabetic group were hypertension, cerebrovascular disease, chronic kidney disease and cardiovascular disease. We discovered that white blood cell count, neutrophil count, inflammatory marker levels, D-dimer, urea, precursor of the brain natriuretic peptide (Pro-BNP) increased and lymphocyte count, estimated glomerular filtration rate (eGFR), albumin decreased significantly in the diabetic group in laboratory test results. …”
  18. 13318

    Image 3_The clinical features and outcomes of diabetes patients infected with COVID-19: a systematic review and meta-analysis comprising 192,693 patients.tif by Kai Liu (159026)

    Published 2025
    “…Common comorbidities in the diabetic group were hypertension, cerebrovascular disease, chronic kidney disease and cardiovascular disease. We discovered that white blood cell count, neutrophil count, inflammatory marker levels, D-dimer, urea, precursor of the brain natriuretic peptide (Pro-BNP) increased and lymphocyte count, estimated glomerular filtration rate (eGFR), albumin decreased significantly in the diabetic group in laboratory test results. …”
  19. 13319

    Image 1_The clinical features and outcomes of diabetes patients infected with COVID-19: a systematic review and meta-analysis comprising 192,693 patients.tif by Kai Liu (159026)

    Published 2025
    “…Common comorbidities in the diabetic group were hypertension, cerebrovascular disease, chronic kidney disease and cardiovascular disease. We discovered that white blood cell count, neutrophil count, inflammatory marker levels, D-dimer, urea, precursor of the brain natriuretic peptide (Pro-BNP) increased and lymphocyte count, estimated glomerular filtration rate (eGFR), albumin decreased significantly in the diabetic group in laboratory test results. …”
  20. 13320

    Data Sheet 1_Retroperitoneal fibrosis in presence of autoimmune coagulation factor XIII deficiency result in recurrent critical post-operative hemorrhage: a case report and molecul... by Tomonori Matsushita (1682554)

    Published 2025
    “…Despite performing one emergency laparotomy and three series of emergency transcatheter arterial embolization along with massive transfusions, achieving hemostasis was difficult. Suspecting a humoral autoimmune hemorrhagic disorder, we performed plasma exchange, which achieved complete hemostasis. …”